厄洛替尼治疗晚期非小细胞肺癌临床观察

The Evaluation of Advanced Non-small Cell Lung Cancer Treated with Erlotinib

目的探讨厄洛替尼单药治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效和不良反应。方法 19例晚期NSCLC患者每天口服150 mg厄洛替尼治疗,直到肿瘤进展或因毒副作用不能耐受而终止治疗为止,评价其临床疗效、症状、生活质量、中位生存期、无疾病进展时间及毒副作用。结果 19例患者病灶总缓解率为26.32%,总控制率为73.68%,临床症状缓解率为78.95%。治疗有效患者治疗后血清癌胚抗原(carcinoem-bry-onic antigen,CEA)水平(16.91±24.95)μg.L-1较治疗前(53.18±38.46)μg.L-1明显降低,治疗后卡氏评分(karnofsky score,KPS)也明显提高(93.57±9.29 vs 57.14±15.90)。中位总生存期为11.4个月,无疾病进展时间11.1个月。不良反应主要为皮疹、腹泻,对症处理后均缓解。结论厄洛替尼治疗晚期NSCLC有一定的疗效,严重不良反应少。

Objective To observe the efficacy and toxicity of Erlotinib in the treatment of patients with advanced non-small cell lung cancer（NSCLC）.Methods Nineteen patients with advanced NSCLC eat Erlotinib 150 mg per day.Until disease progression or ocwrrence of into lerable toxicity.Valuations were made for curative effects,symptoms,quality of life,mean survival time,time to progression-free and toxic reactions.Results Total mitigative rate of the focus was 26.32%,total control rate was 73.68%,all eviativerate of clinical symptoms was 78.95% and the levels of carcinoembryonic antigen（CEA） in the effective patients after treatment were significantly lower than those before the treatment（16.91±24.95 vs 53.18±38.46）μg·L-1.Meanwhile,kam of sky core（KPS） in the effective patients after treatment were obviously increased more than those before treatment（93.57±9.29 vs 57.14±15.90）.Mean survival time of all the patients was 11.4 months.Time to progression-free was 11.1 months.The adverse reactions were mainly rash and diarrhea which could been released by treatments.Conclusion Erlotinib is effective and has fewer serious adverse reaction in treatment of patients with advanced NSCLC.